Quarterly report pursuant to Section 13 or 15(d)

Segments

v2.4.0.8
Segments
6 Months Ended
Jun. 30, 2013
Segment Reporting [Abstract]  
SEGMENTS
SEGMENTS
We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain and Brazil. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OURLab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended June 30,
 
For the six months ended June 30,
(In thousands)
2013
 
2012
 
2013
 
2012
Product revenues:
 
 
 
 
 
 
 
Pharmaceuticals
$
18,618

 
$
9,917

 
$
34,145

 
$
18,556

Diagnostics

 

 

 

Corporate

 

 

 

 
$
18,618

 
$
9,917

 
$
34,145

 
$
18,556

Revenue from services and transfer of intellectual property:
 
 
 
 
 
 
 
Pharmaceuticals
$
1,300

 
$

 
$
13,800

 
$

Diagnostics
3,823

 
243

 
7,132

 
330

Corporate
80

 
51

 
120

 
102

 
$
5,203

 
$
294

 
$
21,052

 
$
432

Operating (loss) income:
 
 
 
 
 
 
 
Pharmaceuticals
$
(4,528
)
 
$
(1,955
)
 
$
3,955

 
$
(3,317
)
Diagnostics
(6,750
)
 
(4,356
)
 
(16,384
)
 
(9,025
)
Corporate
(5,762
)
 
(3,030
)
 
(10,787
)
 
(5,846
)
Less: Operating loss attributable to noncontrolling interests
(943
)
 

 
(1,540
)
 

 
$
(17,983
)
 
$
(9,341
)
 
$
(24,756
)
 
$
(18,188
)
Depreciation and amortization:
 
 
 
 
 
 
 
Pharmaceuticals
$
1,702

 
$
1,575

 
$
3,397

 
$
3,025

Diagnostics
1,704

 
835

 
3,393

 
1,669

Corporate
45

 
44

 
90

 
88

 
$
3,451

 
$
2,454

 
$
6,880

 
$
4,782

Revenues:
 
 
 
 
 
 
 
United States
$
5,203

 
$
294

 
$
21,052

 
$
432

Chile
8,482

 
7,187

 
16,223

 
12,888

Spain
5,153

 

 
9,477

 

Israel
3,995

 
1,518

 
6,567

 
3,145

Mexico
988

 
1,212

 
1,878

 
2,523

 
$
23,821

 
$
10,211

 
$
55,197

 
$
18,988

(In thousands)
June 30,
2013
 
December 31,
2012
Assets:
 
 
 
Pharmaceuticals
$
336,266

 
$
142,299

Diagnostics
114,095

 
112,422

Corporate
190,719

 
35,109

 
$
641,080

 
$
289,830

Goodwill:
 
 
 
Pharmaceuticals
$
34,480

 
$
32,844

Diagnostics
47,606

 
47,606

Corporate

 

 
$
82,086

 
$
80,450


During the three and six months ended June 30, 2013 and 2012, no customer represented more than 10% of our total revenue. As of June 30, 2013 and December 31, 2012, no customer represented more than 10% of our accounts receivable balance.